Stock Scorecard



Stock Summary for Werewolf Therapeutics Inc (HOWL) - $1.33 as of 6/10/2025 9:10:59 PM EST

Total Score

8 out of 30

Safety Score

28 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for HOWL

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for HOWL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for HOWL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for HOWL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for HOWL (28 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 5
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 2
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 8
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for HOWL

Werewolf Therapeutics ( HOWL ) Upgraded to Buy: Here's What You Should Know 5/29/2025 4:00:00 PM
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference 5/29/2025 12:00:00 PM
Voyager Therapeutics ( VYGR ) Reports Q1 Loss, Lags Revenue Estimates 5/6/2025 9:10:00 PM
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease ( IBD ) at AAI Annual Meeting 5/5/2025 12:05:00 PM
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease ( IBD ) at AAI Annual Meeting 5/5/2025 12:05:00 PM
Werewolf Therapeutics to Participate in Upcoming Investor Conferences 5/5/2025 12:00:00 PM
Werewolf Therapeutics to Participate in Upcoming Investor Conferences 5/5/2025 12:00:00 PM
Earnings Preview: Werewolf Therapeutics, Inc. ( HOWL ) Q1 Earnings Expected to Decline 4/25/2025 2:00:00 PM
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer 4/17/2025 12:00:00 PM
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update 3/11/2025 11:00:00 AM

Financial Details for HOWL

Company Overview

Ticker HOWL
Company Name Werewolf Therapeutics Inc
Country USA
Description Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 1.33
Price 4 Years Ago 11.91
Last Day Price Updated 6/10/2025 9:10:59 PM EST
Last Day Volume 956,155
Average Daily Volume 589,211
52-Week High 4.18
52-Week Low 0.59
Last Price to 52 Week Low 125.42%

Valuation Measures

Trailing PE N/A
Industry PE 22.61
Sector PE 41.05
5-Year Average PE -1.66
Free Cash Flow Ratio 0.64
Industry Free Cash Flow Ratio 17.69
Sector Free Cash Flow Ratio 32.85
Current Ratio Most Recent Quarter 8.09
Total Cash Per Share 2.07
Book Value Per Share Most Recent Quarter 1.28
Price to Book Ratio 1.11
Industry Price to Book Ratio 34.46
Sector Price to Book Ratio 30.00
Price to Sales Ratio Twelve Trailing Months 55.75
Industry Price to Sales Ratio Twelve Trailing Months 121.70
Sector Price to Sales Ratio Twelve Trailing Months 34.16
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 44,873,600
Market Capitalization 59,681,888
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -88.70%
Reported EPS 12 Trailing Months -1.64
Reported EPS Past Year -0.40
Reported EPS Prior Year -1.61
Net Income Twelve Trailing Months -72,411,000
Net Income Past Year -70,515,000
Net Income Prior Year -37,368,000
Quarterly Revenue Growth YOY -100.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -6,511.00%

Balance Sheet

Total Cash Most Recent Quarter 92,933,000
Total Cash Past Year 110,995,000
Total Cash Prior Year 134,343,000
Net Cash Position Most Recent Quarter 66,348,000
Net Cash Position Past Year 84,900,000
Long Term Debt Past Year 26,095,000
Long Term Debt Prior Year 32,656,000
Total Debt Most Recent Quarter 26,585,000
Equity to Debt Ratio Past Year 0.74
Equity to Debt Ratio Most Recent Quarter 0.68
Total Stockholder Equity Past Year 73,390,000
Total Stockholder Equity Prior Year 111,374,000
Total Stockholder Equity Most Recent Quarter 57,307,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -59,982,000
Free Cash Flow Per Share Twelve Trailing Months -1.34
Free Cash Flow Past Year -56,442,000
Free Cash Flow Prior Year -33,381,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.10
MACD Signal 0.08
20-Day Bollinger Lower Band 0.66
20-Day Bollinger Middle Band 1.13
20-Day Bollinger Upper Band 1.60
Beta 0.66
RSI 67.47
50-Day SMA 1.72
150-Day SMA 3.06
200-Day SMA 4.75

System

Modified 6/10/2025 1:56:10 AM EST